-
1991
Company Description
EntreMed is a pharmaceutical company developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
-
Manufacturer:
Science and Engineering -
Formed:
1991 -
Company Website:
-
Company E-mail:
-
Company Address:
9640 Medical Center DriveRockville -
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits